hrp0095p2-280 | Thyroid | ESPE2022

From overt hyperthyroidism to normal thyroid function in TSH receptor activating mutations: reports of two families with novel pathogenetic variants and suggestion of a phenotypical sexual dimorphism

Citterio Valeria , Giavoli Claudia , Stellaria Grassi Elisa , Rurale Giuditta , Profka Eriselda , Rodari Giulia , Giacchetti Federico , Collini Valentina , Campi Irene , Arosio Maura , Persani Luca

Introduction: Familial non-autoimmune autosomal dominant hyperthyroidism (FNAH) is a rare cause of childhood hyperthyroidism caused by an activating variant of the thyroid stimulating hormone receptor (TSHR) gene. This disorder may occur as a result of an autosomal dominant inheritance or sporadically through de novo variation. The severity of hyperthyroid symptoms is variable and phenotype differences have been described in subjects harbouring the same mutati...

hrp0092rfc14.3 | Adrenals and HP Axis | ESPE2019

MicroRNAs Change and Target Key Regulatory Genes Involved in Longitudinal Growth in Patients with Idiopathic Isolated Growth Hormone Deficiency (IGHD) on Growth Hormone (GH) Treatment

Cirillo Francesca , Catellani Cecilia , Lazzeroni Pietro , Sartori Chiara , Ravegnini Gloria , Bonvicini Federico , Predieri Barbara , Amarri Sergio , Iughetti Lorenzo , Angelini Sabrina , Elisabeth Street Maria

The growth response in patients undergoing GH treatment is variable depending both on the patient's basal conditions and on personal innate sensitivity to therapy. MicroRNAs (miRNAs) are epigenetic regulators of gene expression, and are recognised as important regulators of biological and metabolic processes. It is unknown at present whether miRNAs could be early biomarkers of response to GH treatment in a perspective of individualised medicine, and whether they could disc...

hrp0089p1-p145 | GH & IGFs P1 | ESPE2018

Response to Growth Hormone in Patients with Isolated Familial Growth Hormone Deficiency due to RNPC3 Mutations

Travieso-Suarez Lourdes , Martos-Moreno Gabriel , Pozo Jesus , Munoz-Calvo Maria , Chowen Julie , Frilander Mikko , Perez-Jurado Luis , Hawkins Federico , Argente Jesus

Background: We recently reported three children with severe isolated growth hormone (GH) deficiency and pituitary hypoplasia due to biallelic mutations in the RNPC3 gene, which codes for a minor spliceosome protein required for U11/U12 small nuclear ribonucleoprotein formation and splicing of U12-type introns. Although it is clear that these patients are GH deficient, the underlying mechanism for this deficit is not totally understood.Objective:...

hrp0086rfc9.4 | Pathophysiology of Disorders of Insulin Secretion | ESPE2016

Prevalence of Monogenic Diabetes in the Lithuanian Pediatric and Young Adult Population

Schwitzgebel Valerie , Dirlewanger Mirjam , Klee Philippe , Santoni Federico , Blouin Jean-Louis , Razanskaite-Virbickiene Dovile , Danyte Evalda , Dobrovolskiene Rimante , Marciulionyte Dalia , Stankute Ingrida , Verkauskiene Rasa

Background: Monogenic diabetes is a heterogeneous group of metabolic disorders resulting from defects in single genes. Over 90% of the subjects remain undiagnosed, mainly because of lack of access to genetic testing.Objective and hypotheses: The aim of our study was to do a comprehensive genetic analysis of the whole pediatric and young adult autoimmune antibody negative diabetes population of Lithuania.Method: 860 children (age 0&...

hrp0094p1-122 | Growth A | ESPE2021

Short stature in Protein Arginine Methyltransferase 7 (PRMT7) mutations: first evidences of growth response to rGH treatment

Rodari Giulia , Giacchetti Federico , Villa Roberta , Scuvera Giulietta , Gangi Silvana , Porro Matteo , Bedeschi Maria Francesca , Profka Eriselda , Dall’Antonia Alberta , Arosio Maura , Giavoli Claudia ,

Protein arginine methyltransferase 7 (PRMT7), a member of a family of enzymes that catalyse the transfer of methyl groups from S-adenosyl-L-methionine to nitrogen atoms on arginine residues, is involved in multiple biological processes, such as signal transduction, mRNA splicing, transcriptional control, DNA repair, and protein translocation. Currently, 12 patients with homozygous/compound heterozygous mutations in PRMT7 gene have been described defining the ...

hrp0095p1-93 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Measurements of Growth Hormone in neonatal screening cards as a non-invasive and feasible tool: reference values in healthy term newborns.

Giacchetti Federico , Vidali Matteo , Sangiorgio Andrea , Rodari Giulia , Vantaggiato Chiara , Modugno Adriana Di , Morniroli Daniela , Colombo Lorenzo , Profka Eriselda , Dall'Antonia Alberta , Collini Valentina , Ceriotti Ferruccio , Mosca Fabio , Arosio Maura , Lorella Giannì Maria , Giavoli Claudia

Background: Severe congenital growth hormone deficiency (cGHD) is a rare but potentially life-threatening condition. Even though random growth hormone (GH) can confirm cGHD during the first week of life, the diagnosis remains extremely challenging in the absence of reliable reference values in healthy neonates and thus of a best diagnostic cut-off.Aims: First, to provide solid reference values for GH concentrations in te...

hrp0092fc2.3 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Higher Dose of Burosumab is Needed for Treatment of Children with Severe Forms of X-Linked Hypophosphatemia

Zhukouskaya Volha , Audrain Christelle , Lambert Anne-Sophie , Kamenicky Peter , Adamsbaum Catherine , Nevoux Jerome , Chaussain Catherine , Wicart Philippe , Briot Karine , Di Rocco Federico , Colao Annamaria , Di Somma Carolina , Trabado Séverine , Prié Dominique , Rothenbuhler Anya , Linglart Agnès

Background/Aim: X-linked hypophosphatemia (XLH) is a rare disease caused by mutations in PHEX, leading to elevated FGF23 levels, hypophosphatemia and chronic renal phosphate wasting. Burosumab is a monoclonal antibody against anti-FGF23, which has been recently approved for treatment of XLH. Beyond clinical trials, little is known about its efficacy/safety in clinical practice which is the aim of study.Patients/Methods: ...

hrp0094p1-58 | Bone B | ESPE2021

AAV liver gene therapy-mediated inhibition of FGF23 signaling as a therapeutic strategy for X-linked hypophosphatemia

Zhukouskaya Volha , Jauze Louisa , Charles Severine , Leborgne Christian , Hilliquin Stephane , Sadoine Jeremy , Slimani Lotfi , Baroukh Brigitte , Wittenberghe Laetitia van , Daniele Natalie , Rajas Fabienne , Linglart Agnes , Mingozzi Federico , Chaussain Catherine , Bardet Claire , Ronzitti Giuseppe ,

Adeno-associated virus (AAV) gene therapy reached the maturity and a liver-targeting approach is currently used as a replacement treatment for rare hepatic and muscular diseases. X-linked hypophosphatemia (XLH) is a rare disease associated with hyperfunction of fibroblast growth factor 23 (FGF23) in bone and characterized by severe skeletal deformities and short stature. The current medical therapies for XLH requires life-long repeated treatment presenting major limitatio...

hrp0089p3-p147 | Fat, Metabolism and Obesity P3 | ESPE2018

Bariatric Surgery as Treatment of Primary Pseudotumor cerebriin a Male Adolescent: Case Report

Ybarra Marina , Jeronimo dos Santos Tiago , Santos Queiroz Edjane , Rachid Ludmilla , Rocha Franco Ruth , Cominato Louise , Castelo Moura Frederico , Carlos Velhote Manoel , Damiani Durval

Introduction: Primary Pseudotumor cerebri (PPTC), also known as idiopathic intracranial hypertension, is clinically characterized by increased intracranial pressure in an alert and oriented patient, with no evidence of deformity or obstruction of the ventricular system on neuroimaging. Cerebrospinal fluid analysis is normal except for increased intracranial pressure at lumbar puncture, greater than the 90th percentile (28 cm of H2O) in the pediatric population. Papilledema may...

hrp0095fc9.4 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Delayed puberty: unraveling the different trajectories and contributions of AI

Antoniou Maria-Christina , Xu Cheng , Zouaghi Yassine , Papadakis Georgios , Stoppa-Vaucher Sophie , Kolesinska Zofia , Bouthors Thérèse , Lore Ruiz Arana Inge , Elowe-Gruau Eglantine , Phan-Hug Franziska , Pasquier Jerôme , Adamo Michela , Deladoey Johnny , Vuissoz Jean-Marc , Busiah Kanetee , Hauschild Michael , Santoni Federico , Acierno James , Pitteloud Nelly

Introduction: Differentiation between constitutional delay of growth and puberty (CDGP) and congenital hypogonadotropic hypogonadism (CHH) during early adolescence is challenging, as patients exhibit a similar clinical picture and there are no definite clinical or biochemical markers that distinguish these 2 pathologies. A delay in diagnosis, especially for CHH, may have short and long-term health consequences. The aims of this study were: 1) To evaluate the u...